# Phase 1/2 cancer trials recruiting: 760 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 760 trials in phase 1/2 for cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 cancer trials: 760 rows for $38, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 16 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 760
- Recruiting or not yet: 760
- Read on: November 19, 2026

## Trials

The 25 newest of 760, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07947134 | A Study of GSK5864399 Administered Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumours | GlaxoSmithKline | Phase 1/2 | Not yet recruiting | Solid Tumours | 155 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07947134) |
| November 18, 2026 | NCT07945821 | A Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors | Coherus Oncology, Inc. | Phase 1/2 | Recruiting | Solid Tumor | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07945821) |
| November 18, 2026 | NCT07944144 | A Phase I/II Study to Learn About the Safety and Effects of a New Medicine Called IPN60350 Alone or in Combination With Other Anticancer... | Ipsen | Phase 1/2 | Not yet recruiting | Neoplasms, Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes | 205 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07944144) |
| November 17, 2026 | NCT07941362 | 177Lu-ACT319 in FAP Expressing Solid Tumors | Actithera INC. | Phase 1/2 | Not yet recruiting | FAP-expressing Solid Tumors, Pancreatic Ductal Adenocarcinoma (PDAC), Biliary Tract Carcinoma (BTC) | 182 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941362) |
| November 16, 2026 | NCT07939815 | A Study of BMS-986548 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies | Bristol-Myers Squibb | Phase 1/2 | Not yet recruiting | Advanced Solid Malignancies | 171 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939815) |
| November 12, 2026 | NCT07933419 | Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid Tumors | Qilu Pharmaceutical Co., Ltd. | Phase 1/2 | Not yet recruiting | Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Other Advanced Solid Tumors | 558 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933419) |
| November 6, 2026 | NCT07921576 | Phase 1/2 Study of DS010 in Advanced Cancer Patients With Cachexia | Dartsbio Pharmaceuticals Ltd. | Phase 1/2 | Recruiting | Cancer, Cachexia | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07921576) |
| November 4, 2026 | NCT07917390 | ALT-100 Monoclonal Antibody (mAb) in Bone-Predominant Metastatic Androgen Pathway Modulation Resistant (APMR) Prostate Cancer -- The... | University of Florida | Phase 1/2 | Not yet recruiting | Prostate Cancer Metastatic to Bone | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917390) |
| November 3, 2026 | NCT07912593 | A KRAS Inhibitor in Participants With Advanced Solid Tumors | Ensem Therapeutics | Phase 1/2 | Recruiting | Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Non-squamous, Non-Small Cell Lung Cancer... | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07912593) |
| November 2, 2026 | NCT07909031 | CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors | Crescent Biopharma, Inc. | Phase 1/2 | Recruiting | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC)... | 219 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909031) |
| October 29, 2026 | NCT07905131 | A Study of Perioperative Navlimetostat Combined With Modified FOLFIRINOX in Patients With MTAP-Deleted Pancreatic Cancer | Sponsor not shown (see the record) | Phase 1/2 | Not yet recruiting | Pancreatic Ductal Adenocarcinoma (PDAC) | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905131) |
| October 29, 2026 | NCT07902921 | STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic... | National Cancer Institute (NCI) | Phase 1/2 | Not yet recruiting | NSCLC, Non-Small Cell Lung Cancer, Lung Cancer, Prostate Cancer, Thymic Epithelial Tumors, TETs, Thymic Carcinomas... | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902921) |
| October 28, 2026 | NCT07900165 | Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer | CytomX Therapeutics | Phase 1/2 | Not yet recruiting | Colo-rectal Cancer | 368 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900165) |
| October 27, 2026 | NCT07899632 | A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors | Medsyn Biopharma, LLC | Phase 1/2 | Not yet recruiting | Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer... | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899632) |
| October 27, 2026 | NCT07897734 | TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and... | Tango Therapeutics, Inc. | Phase 1/2 | Not yet recruiting | PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation, MTAP Deletion, Lung Cancer, Pancreatic Cancer... | 188 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897734) |
| October 27, 2026 | NCT07897227 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SYS6062 in Patients With Advanced Solid Tumors. | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 1/2 | Not yet recruiting | Advanced Solid Tumors, Gastric Cancer (GC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC) | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897227) |
| October 15, 2026 | NCT07876128 | A Clinical Trial of MK-2750 in Participants With Advanced Solid Tumors (MK-2750-002) | Merck Sharp & Dohme LLC | Phase 1/2 | Not yet recruiting | Advanced Solid Tumors, Malignant Neoplasm | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876128) |
| October 14, 2026 | NCT07874347 | Home-Based Outpatient Model for BCG Delivery to Reduce Undue Burden on Patients Undergoing Treatment for Non-Muscle Invasive Bladder... | Ohio State University Comprehensive Cancer Center | Phase 1/2 | Not yet recruiting | Non-Muscle Invasive Bladder Carcinoma | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874347) |
| October 14, 2026 | NCT07873827 | KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme Malignancies | Stemline Therapeutics, Inc. | Phase 1/2 | Not yet recruiting | Hematological Malignancy | 115 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873827) |
| October 14, 2026 | NCT07873450 | SumMET: Study of \[225Ac\]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET | Full-Life Technologies UK Limited | Phase 1/2 | Recruiting | Solid Tumor, NSCLC, Colorectal Cancer, Head and Neck Cancer, Cholangiocarcinoma | 208 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873450) |
| October 8, 2026 | NCT07864584 | Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced... | Nob Hill Therapeutics, Inc. | Phase 1/2 | Not yet recruiting | NSCLC (Advanced Non-small Cell Lung Cancer) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07864584) |
| October 7, 2026 | NCT07863024 | Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET... | Regeneron Pharmaceuticals | Phase 1/2 | Recruiting | Advanced Solid Tumors | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07863024) |
| October 7, 2026 | NCT07862582 | RYZ711 Diagnostic Platform Study | RayzeBio, Inc. | Phase 1/2 | Recruiting | Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate, Metastatic Castration-resistant Prostate Cancer... | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07862582) |
| October 6, 2026 | NCT07861932 | A Phase 1/2a Study of K-1728 in Advanced Solid Tumors | KymaThera, Inc. | Phase 1/2 | Recruiting | Breast Neoplasms, Solid Tumors, PIK3CA Gene Mutation | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861932) |
| October 5, 2026 | NCT07857135 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid Tumors | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 1/2 | Not yet recruiting | Advanced/Metastatic Solid Tumors | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07857135) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National Cancer Institute (NCI) | 21 |
| [Beijing Biotech](https://specstream.ai/data/clinical-trials/company/beijing-biotech) | 16 |
| M.D. Anderson Cancer Center | 14 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 13 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 10 |
| Fudan University | 10 |
| Essen Biotech | 10 |
| West China Hospital | 8 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 7 |
| Shenzhen Geno-Immune Medical Institute | 7 |
| [Jiangsu HengRui Medicine Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hengrui-medicine-co-ltd) | 6 |
| [Revolution Medicines, Inc.](https://specstream.ai/data/clinical-trials/company/revolution-medicines-inc) | 5 |
| Memorial Sloan Kettering Cancer Center | 5 |
| Jacobio Pharmaceuticals Co., Ltd. | 5 |
| [Gilead Sciences](https://specstream.ai/data/clinical-trials/company/gilead-sciences) | 5 |
| Washington University School of Medicine | 5 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 5 |
| University of Florida | 5 |
| [BioNTech SE](https://specstream.ai/data/clinical-trials/company/biontech-se) | 5 |
| National University Hospital, Singapore | 4 |
| Cancer Research UK | 4 |
| LaNova Medicines Limited | 4 |
| DualityBio Inc. | 4 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 4 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 4 |

## By country

| Country | Trials |
| --- | --- |
| United States | 374 |
| China | 243 |
| Australia | 83 |
| Spain | 81 |
| France | 68 |
| United Kingdom | 66 |
| South Korea | 63 |
| Italy | 49 |
| Canada | 47 |
| Germany | 47 |
| Japan | 41 |
| Netherlands | 35 |
| Taiwan | 33 |
| Belgium | 28 |
| Israel | 19 |
| Poland | 16 |
| Brazil | 14 |
| Sweden | 13 |
| Denmark | 13 |
| Singapore | 12 |
| Turkey (Türkiye) | 11 |
| Switzerland | 11 |
| Chile | 10 |
| Norway | 9 |
| Puerto Rico | 8 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Ramen restaurants in the United States](https://specstream.ai/data/businesses/ramen-restaurants/united-states)
- [Vocational and technical schools in the United States](https://specstream.ai/data/businesses/vocational-and-technical-schools/united-states)
- [Boat and ship manufacturers in the United States](https://specstream.ai/data/businesses/boat-and-ship-manufacturers/united-states)
- [Elementary schools in the United States](https://specstream.ai/data/businesses/elementary-schools/united-states)
- [Instrumentation engineers in the United States](https://specstream.ai/data/businesses/instrumentation-engineers/united-states)
- [Pediatric cardiology practices in the United States](https://specstream.ai/data/businesses/pediatric-cardiology-practices/united-states)
